Meaning-Making Narratives Within a Puzzle of Parts: A Psychobiographical Sketch of Sylvia Plath

This study aimed to unveil Sylvia Plath’s (1932–1963) meaning-making narratives, within her life’s puzzle of parts, by utilising the Internal Family System (IFS) model of Schwartz. Plath was purposively selected as subject since she has been proclaimed as one of the most renowned and influential voices in 20th century Anglo-American culture and literature. Although she only published one collection of poems, “The Collosus”, and one novel, “The Bell Jar”, in her lifetime, the plethora of short stories, poems, journal entries and letters which were published after her suicide secured her status as a powerful and creative voice. Methodological strategies utilised to sort and integrate the wealth of publically-available socio-historical data on Plath included the analysis of psychobiographical indicators of salience according to the model of Irving Alexander and the data analysis matrix procedure of Robert Yin. Findings suggest that each stage of Plath’s life was characterised by “parts-led” functioning as a result of transferred burdens, imperfect care-taking, existential anxiety and traumatic emotional experiences. This resulted in polarisation of her different parts, which blocked the healing energy of her Self and aggravated feelings of worthlessness, in spite of her creative meaning-making narratives. Since Sylvia used her creative genius to address socio-historical issues and injustices, her life lends itself to meaning-making narratives, especially those that empower and inspire future generations of previously disempowered groups

Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: A randomised, placebo-controlled trial in AIDS patients

This phase IIa, randomised, single-blind, placebo-controlled study was conducted to determine the dose of recombinant human granulocyte colony-stimulating factor (lenograstim) suitable for use in AIDS patients. The study was conducted at 27 European AIDS/HIV centres, and recruited 69 AIDS patients with an initial episode or relapse of cytomegalovirus infection (neurological site excluded) and an absolute neutrophil count (ANC) less than or equal to1.0 x 10(9)/L upon diagnosis or between days 1 and 12 of ganciclovir (GCV) treatment. The patients were randomised to placebo (n = 14) or one of four lenograstim arms: 150 mug/m(2)/d (the standard onco-haematology dose, II = 13) or 100 (n = 13), 50 (n = 15), or 25 mug/m(2)/d (n = 14). In all groups, the planned dose of GCV was 10 mg/kg/d for 21 d. Median ANC at weeks 2 and 3 was significantly higher in each lenograstim group than in the placebo group (p = 0.05). At week 3, median ANC (x 10(9)/L) was 0.7 in the placebo group, compared with 6.0, 7.4, 4.5, and 2.0 in the 150, 100, 50, and 25 mug(2)/d lenograstim groups, respectively. Median ANC was not significantly different between the 150, 100, and 50 mug/m(2)/d lenograstim groups at any time point, but significantly higher in the 50 than in the 25 mug/m(2)/d group at weeks 2 (p = 0.05) and 3 (p = 0.02). Lenograstim was generally well tolerated, leading to no severe adverse events. In conclusion, lenograstim 50 mug/m(2)/d is suitable for the treatment of ganciclovir-induced neutropenia and is safe. These results should help the physician choose an optimal and cost-efficient regimen for patients with AIDS-related neutropenia when rHuG-CSF support is indicated